Display options
Share it on

World J Hepatol. 2021 Mar 27;13(3):362-374. doi: 10.4254/wjh.v13.i3.362.

Early tacrolimus exposure does not impact long-term outcomes after liver transplantation.

World journal of hepatology

Mikel Gastaca, Patricia Ruiz, Javier Bustamante, Lorea Martinez-Indart, Alberto Ventoso, José Ramón Fernandez, Ibone Palomares, Mikel Prieto, Milagros Testillano, Patricia Salvador, Maria Senosiain, Maria Jesus Suárez, Andres Valdivieso

Affiliations

  1. Department of HPB Surgery and Liver Transplantation Unit, Hospital Universitario Cruces, Bilbao 48903, Spain. [email protected].
  2. Department of HPB Surgery and Liver Transplantation Unit, Hospital Universitario Cruces, Bilbao 48903, Spain.
  3. Department of Hepatology Unit, Hospital Universitario Cruces, Bilbao 48903, Spain.
  4. Department of Bioinformatics and Statistics Platform, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, Bilbao 48903, Spain.

PMID: 33815678 PMCID: PMC8006083 DOI: 10.4254/wjh.v13.i3.362

Abstract

BACKGROUND: Tacrolimus trough levels (TTL) during the first weeks after liver transplantation (LT) have been related with long-term renal function and hepatocellular carcinoma recurrence. Nevertheless, the significance of trough levels of tacrolimus during the early post-transplant period for the long-term outcome is under debate.

AIM: To evaluate the effect of TTL during the first month on the long-term outcomes after LT.

METHODS: One hundred fifty-five LT recipients treated

RESULTS: Mean levels within the first month post-transplant were 7.4 ± 1.7 and 12.6 ± 2.2 ng/mL in the ≤ 10 and > 10 groups, respectively. Donor age was higher in the high TTL group 62.9 ± 16.8 years

CONCLUSION: Differences in tacrolimus levels restricted to the first month after transplant did not result in significant differences in long-term outcomes of LT recipients.

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Keywords: Liver transplantation; Once-daily tacrolimus; Outcomes; Prolonged released tacrolimus; Renal function; Survival; Tacrolimus levels

Conflict of interest statement

Conflict-of-interest statement: MG is a member of advisory boards and has received honoraria from Astellas, Novartis and Chiesi. JB has received honoraria from Astellas and Novartis. AV has received h

References

  1. Am J Transplant. 2010 Oct;10(10):2296-304 - PubMed
  2. J Hepatol. 2014 Aug;61(2):286-92 - PubMed
  3. Am J Transplant. 2009 Feb;9(2):327-36 - PubMed
  4. Transplantation. 2019 Dec;103(12):2539-2548 - PubMed
  5. Liver Transpl. 2009 Nov;15 Suppl 2:S70-4 - PubMed
  6. Am J Transplant. 2011 May;11(5):965-76 - PubMed
  7. N Engl J Med. 2003 Sep 4;349(10):931-40 - PubMed
  8. Liver Transpl. 2016 Oct;22(10):1391-400 - PubMed
  9. Liver Transpl. 2009 Nov;15 Suppl 2:S83-9 - PubMed
  10. Clin Ther. 2002 Mar;24(3):330-50; discussion 329 - PubMed
  11. Ann Surg. 2008 Nov;248(5):857-62 - PubMed
  12. Am J Transplant. 2010 Jun;10(6):1420-7 - PubMed
  13. J Hepatol. 2013 Feb;58(2):262-70 - PubMed
  14. Transplantation. 2011 May 15;91(9):1025-30 - PubMed
  15. Kidney Int. 2005 Jun;67(6):2089-100 - PubMed
  16. Liver Transpl. 2010 Aug;16(8):943-9 - PubMed
  17. World J Gastroenterol. 2014 Aug 28;20(32):11363-9 - PubMed
  18. Liver Transpl. 2013 Jan;19(1):3-26 - PubMed
  19. Liver Transpl. 2009 Sep;15(9):1083-91 - PubMed
  20. J Hepatol. 2013 Dec;59(6):1193-9 - PubMed
  21. Hepatology. 1997 Mar;25(3):658-63 - PubMed
  22. Am J Transplant. 2017 Jan;17 Suppl 1:174-251 - PubMed
  23. PLoS One. 2014 Jun 06;9(6):e98782 - PubMed
  24. Am J Transplant. 2012 Oct;12(10):2797-814 - PubMed

Publication Types